Clinical Trials on Type 2 Diabetes Mellitus, Non Insulin Dependent in Austria

Total 700 results

University of Cambridge
Medical University of Graz; Cambridge University Hospitals NHS Foundation Trust and other collaborators

Completed

Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes (AP@home02)

Type 1 Diabetes

United Kingdom, Germany, Austria
Novo Nordisk A/S

Completed

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Italy, Mexico, Poland, Russian Federation, Spain, Canada, Denmark, Taiwan, Malaysia, United Kingdom, Turkey, Germany, Bulgaria, Argentina, Australia, Thailand, Algeria, Brazil
Eli Lilly and Company

Completed

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (IOOV)

Diabetes Mellitus, Type 2

United States, Canada, India, Puerto Rico, Australia, Spain, Netherlands, Hungary, Brazil, Greece, Romania, Argentina
Bayside Health

Completed

Dietary Advanced Glycation End-products and Insulin Resistance in Overweight and Obese Humans

Obesity | Insulin Resistance | Type 2 Diabetes

Australia
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (Ellipse™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Russian Federation, Spain, United Kingdom, Austria, Belgium, Mexico, Sweden, Israel, Taiwan, Hungary, Malaysia, Serbia, Turkey, Denmark, Greece, Thailand, North Macedonia, Norway, Portugal, Germany, Romania and more
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec (COMBINE 1)

Diabetes Mellitus, Type 2

Finland, Taiwan, United States, Korea, Republic of, China, Australia, Portugal, Japan, India, Russian Federation, Norway, Italy, Mexico, Turkey, Poland, Belgium, Bulgaria, Croatia, Puerto Rico, Romania, Serbia, South Africa
Lexicon Pharmaceuticals
Sanofi

Completed

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control (SOTA-CKD3)

Type 2 Diabetes Mellitus | Chronic Kidney Disease Stage 3

United States, Argentina, Brazil, Canada, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
Novo Nordisk A/S

Completed

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, Poland, South Africa, Slovakia
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) (ONWARDS 3)

Diabetes Mellitus, Type 2

United States, Mexico, Puerto Rico, Canada, Denmark, France, Austria, Taiwan, Czechia, Brazil, China, Argentina
Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

Diabetes Mellitus, Type 2

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study for Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Puerto Rico, United States, Romania, United Kingdom, Spain, Mexico, Austria, South Africa, Germany, Ukraine, India
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Spain, Denmark, Austria, Belgium, Serbia, Germany, Canada, France, Finland, Norway, Czech Republic
Eisai Inc.
Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization

Completed

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI)

Obesity | Cardiovascular Disease | Overweight | Type 2 Diabetes | High Cardiovascular Risk

United States, Canada, Poland, Australia, Mexico, New Zealand, Bahamas, Chile
Hoffmann-La Roche
Roche Diabetes Care GmbH

Completed

Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes (Insight Kids)

Diabetes Mellitus Type 1

Germany, Austria, United Kingdom
Novo Nordisk A/S

Completed

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Israel, Italy, Mexico, Puerto Rico, Russian Federation, Spain, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Taiwan, Finland, Norway, Serbia, South Africa, Turkey, Canada, France, Germany, Korea, Republic of and more
Novo Nordisk A/S

Completed

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, United Kingdom, Canada, Spain, Denmark, Austria, Serbia, South Africa, Sweden, Italy, Bulgaria, Germany, Malaysia
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Slovakia, Greece, Argentina, South Africa, Australia
Novo Nordisk A/S

Completed

Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes (PIONEER PLUS)

Diabetes Mellitus, Type 2

United States, India, Taiwan, Poland, Australia, Estonia, Hungary, Germany, Slovakia, Canada, Croatia, Bulgaria, Puerto Rico, Czechia, Slovenia
Eli Lilly and Company

Completed

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) (AWARD-2)

Diabetes Mellitus, Type 2

Argentina, India, Australia, Spain, Taiwan, France, Canada, Hungary, Mexico, Croatia, Korea, Republic of, Poland, Greece, Belgium, Brazil, Italy, Czech Republic, Romania, Slovakia, Sweden
GlaxoSmithKline

Completed

A Study In Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Canada, Australia, Philippines, Mexico, Puerto Rico
AstraZeneca

Completed

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

Diabetes Mellitus, Type 2

United States, Chile, Argentina, Brazil, Canada, Mexico, Puerto Rico, Taiwan, Australia
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Mexico, Netherlands, Russian Federation, India, Belgium, Japan, Romania, Italy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Brazil, Canada, El Salvador, France, Korea, Republic of, New Zealand, Norway, Spain, Taiwan
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes (DUAL™ II)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Denmark, Hungary, Slovenia, Switzerland, Bulgaria
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Diabetes Mellitus, Type 2

Poland, United States, Croatia, Spain, Slovakia, Germany, Hungary
Novo Nordisk A/S

Completed

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Poland, Slovakia, Canada, Slovenia, Greece, Czechia
Arecor Limited

Completed

AT278 and NovoRapid® in Glucose Clamp Study

Diabetes Mellitus, Type 1

Austria
Eli Lilly and Company

Completed

A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue

Diabetes Mellitus, Type 1

Austria
REMD Biotherapeutics, Inc.

Completed

Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Type1 Diabetes Mellitus

United States
Sanofi

Terminated

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus (SAMS)

Sleep Initiation and Maintenance Disorders

United States, Canada, Brazil, Russian Federation, Australia, Germany, Italy, Spain, Turkey, India, Malaysia, Singapore, Belgium, Czech Republic, Mexico, Argentina, Austria, Colombia, Chile, South Africa, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-1)

Diabetes Mellitus, Type 2 | Diabetes

Israel, Poland, Switzerland, Argentina, India, Malaysia, South Africa, Taiwan, Finland, France, Turkey, Croatia, Italy, Bulgaria, Romania, Australia, Thailand, Greece, Brazil, Spain, Korea, Republic of, Czech Republic, Philippines
Baker Heart Research Institute

Unknown

The Effects of Weight Loss on Neuroadrenergic Function

Obesity | Metabolic Syndrome | Type 2 Diabetes

Australia
University of Texas at Austin

Recruiting

Healthy Liver - Healthy Brain

Metabolic Syndrome | NAFLD | Pre-diabetes | Non-Alcoholic Fatty Liver Disease

United States
Texas Diabetes & Endocrinology, P.A.

Completed

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Austria
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED)

Heart Failure | Chronic Kidney Diseases | Type 2 Diabetes Mellitus

Estonia, Belgium, Sweden, Italy, China, United States, Canada, Bulgaria, Chile, Denmark, Hungary, Latvia, Mexico, Russian Federation, Serbia, Spain, Portugal, Romania, Turkey, Poland, Lithuania, Argentina, Australia, Brazil, Czechia, France, Georg... and more
Novo Nordisk A/S

Completed

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes (STEP HFpEF DM)

Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

United States, Spain, Hungary, United Kingdom, India, Netherlands, Germany, Japan, Canada, Czechia, Argentina, Austria, Israel, Italy, Poland, Sweden
Inventiva Pharma

Active, not recruiting

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Netherlands, United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (PIONEER 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Japan, Puerto Rico, Canada, France, Mexico, Poland, Russian Federation, Greece
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Italy, Puerto Rico, United Kingdom, Argentina, Finland, Serbia, Germany, France, Greece, Netherlands, Switzerland
Sanofi

Completed

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (GALAPAGOS)

Diabetes Mellitus, Type 2

Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Canada, El Salvador, Germany, Italy, Portugal, Russian Federation, Spain, Ukraine
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Spain, Switzerland, Argentina, Finland, Hungary, Russian Federation, Slovenia, Slovakia
University of Cambridge
Medical University of Graz; University Hospital Inselspital, Berne; Manchester...

Completed

Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_P3)

Type 1 Diabetes

United Kingdom, Austria, Switzerland
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Spain, Denmark, Austria, Belgium, Serbia, Germany, Slovenia, Canada, France, Finland, Former Serbia and Montenegro, Czech Republic, Norway
Medical University of Vienna

Completed

Glucose Monitoring During Threatening Preterm Birth in Patients With and Without Gestational Diabetes Mellitus

Insulin Sensitivity | Diabetes, Gestational | PreTerm Birth | Glucose Intolerance During Pregnancy | Glucocorticoids

Austria
Janssen Research & Development, LLC

Completed

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Diabetes Mellitus, Type 2

United States, Colombia, Mexico, Poland, Spain, India, Malaysia, Romania, South Africa, Sweden, Korea, Republic of, Estonia, Puerto Rico, Austria, Lithuania, Philippines, Guatemala, Iceland
GlaxoSmithKline

Completed

Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.

Diabetes Mellitus, Type 2

Spain, Germany, France, Austria, Italy
Eli Lilly and Company

Completed

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes (AUTONOMY)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Poland, Canada, Austria, Mexico, Denmark, Croatia, Brazil, Argentina, Romania, South Africa, Russian Federation, France, Lithuania
Calibra Medical, Inc.
Medpace, Inc.

Completed

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, France, United Kingdom, Germany

Clinical Trials on Type 2 Diabetes Mellitus, Non Insulin Dependent in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations